Bradford Graves

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations

Medicine, Oncology, Pharmacology +15

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Yong S. Chang, Bradford Graves, Vincent Guerlavais et al. · Proceedings of the National Academy of Sciences · 2013 · 661 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Qingjie Ding, Zhuming Zhang, Jinjun Liu et al. · Journal of Medicinal Chemistry · 2013 · 597 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano et al. · The Lancet Oncology · 2012 · 563 citations

Medicine, Cancer Biology, Oncology +16

Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains

Bradford Graves, R. Crowther, Chitra Chandran et al. · Nature · 1994 · 397 citations

Life Sciences, Molecular Biology, Protein-protein Interactions +13